Labcorp has made several strategic moves in the past few years that have positively impacted its market position. Labcorp delivered robust Q1 2025 earnings, but its Q1 2025 results reportedly fell below analyst estimates. The company has an optimistic outlook for Q2 2025, with the earnings release set for July 24, 2025. Furthermore,
Barclays has maintained Labcorp's hold rating and raised the target price to $275. Importantly, Labcorp has implemented a 1000+ biomarker platform aimed at holistic healthcare testing, promising a revolution in the field. Novel self-collection options for HPV and STI testing have also been launched. Labcorp has also seen key acquisitions, such as that of select assets from
BioReference Health's innovative oncology and clinical testing services businesses and from
Invitae. Labcorp's
CFO Glenn Eisenberg has announced his retirement plans. Finally, value investors find Labcorp a good buy option, considering its credible performance and a dividend declaration for the quarterly period.
Laboratory Corporation of America Holdings LH News Analytics from Thu, 23 Jul 2020 07:00:00 GMT to Fri, 11 Jul 2025 03:35:00 GMT -
Rating 6
- Innovation 5
- Information 7
- Rumor 1
